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Synovial fluid myeloid dendritic cells display important
differences compared to monocyte-derived dendritic
cells prepared in vitro
Mahin Moghaddami1,2, Michael James1,2, Samuel L Whittle3 and Leslie G Cleland1,2,4
The object of this study was to characterise synovial fluid dendritic cells (SFDCs) with regard to morphology, phenotype and
responses to 1,25hydroxy-cholecalciferol (1,25D) and lipopolysaccharide (LPS), and to compare these characteristics with those
of peripheral blood (PB) monocyte-derived DCs (MDDCs). SF was aspirated from knees with inflammatory effusions. PB samples
were obtained contemporaneously. SFDCs were separated by flow cytometry. Morphology was determined on cytosmears.
Expression of accessory molecules, cytokines and prostaglandin synthases mRNA was quantified by reverse transcription PCR.
Analyses were performed on freshly prepared DCs and after incubation with 1,25D and LPS, separately and in combination.
SFDCs and MDDCs displayed broadly similar morphology. Expression of accessory molecules, cytokines, cyclooxygenase-2
(COX-2) and prostaglandin E-synthase (PGES) was similar. SFDCs, but not MDDCs, expressed prostaglandin D-synthase (PGDS).
PGDS was lost on incubation with SFDCs, but was induced by 1,25D in MDDCs. LPS in the presence or absence of 1,25D,
induced interleukin 23 (IL23), IL1b and tumour necrosis factor-a in SFDCs and MDDCs, with SFDC showing stronger
expression of these cytokines. 1,25D in combination with LPS induced PGES and enhanced LPS induction of IL6 in SFDCs
and MDDCs. LPS reduced 1,25D-induced expression of PGDS in MDDCs. SFDCs and MDDCs display similar basal
characteristics but differ in PGDS expression and responsiveness to LPS and 1,25D. MDDCs have limitations as a model of
SFDCs which have differentiated in vivo.
Clinical & Translational Immunology (2014) 3, e23; doi:10.1038/cti.2014.19; published online 8 August 2014
We have reported that myeloid dendritic cells (DCs) are a substantial
minority population among mononuclear cells within synovial fluid
(SF) from knee effusions in patients with rheumatoid arthritis and
other inflammatory arthropathies.1 We have further shown that DCs
can be separated from other SF mononuclear cells of appropriate size
and complexity by flow cytometry using a selection strategy, which
utilises antibodies against CD11b (on myeloid cells), HLADR
(antigen-presenting cells), CD11c (on human monocytes and DCs)
and CD14 (present on human monocytes but not DCs). The resulting
designation of CD11bþ , HLADRþ , CD11cþ cells as either
DCs (CD14) or monocytes (CD14þ ) has been confirmed by
morphometric analysis of cell smears.1
DCs can be generated in vitro through culture of peripheral blood
(PB) monocytes for 1 week in the presence of granulocyte–
macrophage colony-stimulating factor and interleukin 4 (IL4).
The abundance of the starting population of cells from readily
accessible PB samples and the reliability of the transformation, which
utilises the readily available recombinant proteins, granulocyte–
macrophage colony-stimulating factor and IL4, has led to the use of
monocyte-derived dendritic cells (MDDCs) generated in vitro as a
core resource for the study of DCs.
While MDDCs have gained prominence in studies of human DCs
because of their ready availability, questions remain regarding their
authenticity compared with DCs differentiated in vivo at sites of
inflammation, which provide multiple additional potential influences,
including other cytokines, lipid mediators, adhesion molecules,
stromal and structural elements and other cell types, which are not
represented within in vitro cultures. The ability to isolate SFDCs from
inflammatory knee effusions, coupled with convenience of venepunc-
ture of the same subjects, provided the opportunity to test the
authenticity of MDDCs as a model for DCs accumulating in inflamed
joints of patients with arthritis.
In the studies described herein, we compare SFDCs and MDDCs
with regard to their morphology, accessory molecule expression,
inflammatory cytokine-expression profiles and the expression of
prostaglandin synthases (PGSs) involved in inflammation. Utilising
the same end points, we also examined the respective responses of
SFDCs and MDDCs to two agents, lipopolysaccharide (LPS) and
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1,25hydroxy-cholecalciferol (1,25D), which are known to influence, in
different ways, the outcome of immune responses to immunological
challenge through their effects on DCs. LPS is a complex bacterial cell
wall glycolipid, which activates DCs, monocytes and other myelo-
monocytic cells through engagement of the pattern receptor TLR-4,
thereby generating a ‘danger signal’, which increases immune respon-
siveness. By contrast, 1,25D, the biologically active form of vitamin D,
has been shown to alter DC function in a way that favours
lymphocyte tolerance to presented antigen and militates against
autoimmunity as shown in animal models of multiple sclerosis and
arthritis.2,3 These divergent effects made the outcome of combined
stimulation with LPS and 1,25D of interest.
RESULTS
SFDCs and MDDCs display similar but distinct morphology
SFDCs freshly prepared using flow cytometry (Figure 1) and MDDCs
both displayed the cytoplasmic and cell surface morphology of
immature DCs, that is, medium size with smooth or ruffled borders
(Figures 2a and b). However, the feature of eccentric location of the
nucleus, which is regarded as a typical feature of immature DCs, was
seen in MDDCs (Figure 2b), whereas the indented nucleus was often
more centrally located in many SFDCs (Figure 2a). Culture of both
SFDCs and MDDCs with the TLR-4 ligand LPS yielded the
morphology characteristic of mature DCs (that is, variably located
nuclei and veiled cytoplasm; Figures 2c and d).
SFDCs and MDDCs display similar expression of co-stimulatory
molecules, inflammatory cytokines and the eicosanoid synthases
PGES and COX-2, but differ in PGDS expression
The functional phenotypes of SFDCs and MDDCs were generally
comparable with relatively similar expression of the co-stimulatory
molecules CD80, CD83 and CD86 (Figure 3) and the proinflamma-
tory cytokines IL23, IL1b, tumour necrosis factor-a (TNFa) and IL6
(Figure 4) and the PGSs cyclooxygenase-2 (COX-2) (Figures 5a and
b) and prostaglandin E-synthase (PGES) (Figures 5c and d). A point
of difference was the significant expression of the PGS prostaglandin
D-synthase (PGDS) in SFDCs compared with basal expression by
MDDCs (Po0.01; Figures 5e and f).
Similar effect of LPS on expression of co-stimulatory molecules in
SFDCs and MDDCs
As shown in Figure 3, in both SFDCs and MDDCs, LPS stimulation
yielded significant upregulation of co-stimulatory molecules CD80
(Figures 3a and b) and CD83 (Figures 3c and d) (Po0.05) but not
CD86 (Figures 3e and f). CD14 was downregulated in response to
LPS in both cell types (data not shown).
Differing effects of LPS on expression of cytokines in SFDCs and
MDDCs
Although upon culture with LPS, both SFDCs and MDDCs upregu-
lated IL23 (Figures 4a and b), IL1b (Figures 4c and d) and TNFa
(Figures 4e and f), the expression of these cytokines was substantially
higher in SFDCs compared with MDDCs (Po0.05, note differences
in scales for SFDCs and MDDCs in Figures 4a–f). Upregulation of IL6
by LPS occurred to a similar extent in SFDCs and MDDCs (Figures
4g and h). LPS stimulation weakly upregulated IL12 in both SFDCs
and MDDCs (data not shown).4
Effect of LPS on expression of PGSs
Culture with LPS induced COX-2 in SFDCs and MDDCs (Figures 5a
and b). LPS alone did not maintain nor induce PGDS (Figures 5e
and f) or PGES (Figures 5c and d) expression in either cell type.
Effect of 1,25D on the morphology and phenotype of SFDCs and
MDDCs
Culture with 1,25D for 48h did not alter the morphology of SFDCs
or MDDCs (not shown). Similarly, there was no significant effect of
1,25D on the expression of co-stimulatory molecules CD80, CD83
and CD86 (Figure 3) or of the inflammatory cytokines (Figure 4) in
either SFDCs or MDDCs. Incubation with 1,25D upregulated PGDS
significantly in MDDCs (Figure 5f), whereas the expression of PGDS
was lost from fresh SFDCs when cultured for 2 days in medium with
(Figure 5e) or without 1,25D (not shown in Figure 5, shown in
Supplementary Figure 1). 1,25D alone did not significantly induce
COX-2 (Figures 5a and b) or PGES (Figures 5c and d) in SFDCs and
MDDCs.
Combinatorial effects of 1,25D and LPS on morphology and
phenotype of SFDCs and MDDCs
The presence of 1,25D with LPS did not alter the morphological
changes seen with maturation of SFDCs and MDDCs in response to
LPS alone (not shown). Similarly, addition of 1,25D with LPS did not
significantly alter mRNA expression of the co-stimulatory molecules
CD80, CD83 and CD86 (Figure 3) or the cytokines, IL23, IL1b and
TNFa (Figures 4a–f), or PGS COX-2 (Figures 5a and b) in SFDCs or
MDDCs compared with cells cultured with LPS alone. By contrast, in
SFDCs and MDDCs, substantial further upregulation of IL6 (Figures
4g and h),5,6 and upregulation of PGES (Figures 5c and d), occurred
in response to LPS in the presence of 1,25D (Po0.05). The induction
of PGDS in MDDCs by 1,25D was significantly diminished in the
presence of LPS (Po0.0001; Figure 5f).
Observations with MDDCs prepared from SF CD14þ monocytes
MDDCs prepared from SF CD14þ monocytes showed similar
responses to LPS and 1,25D with regard to morphological changes
and expression of surface molecules and genes of interest compared
with PB MDDCs (data not shown).
DISCUSSION
Comparison between unstimulated SFDCs and MDDCs revealed
many similarities. Cell surface morphology by microscopy and
expression of accessory molecules, the inflammatory cytokines
(IL1b, TNFa, IL6, IL12, IL23) and the PGSs (COX-2 and PGES)
were similar. The main point of difference in unstimulated cells was
the expression of PGDS in SFDCs but not MDDCs. There was also a
morphological difference in the location of the nucleus (variable and












Figure 1 Four colour flow cytometric analysis of cells prepared from SF
aspirates. (a) the selected gate based on forward and side scatter of light;
(b) selection of HLADRþ and CD11bþ cells; (c) shows majority of
HLADRþ CD11bþCD11cþ cells are CD14þ monocytes and 15% are
CD14 myeloid DCs.
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The basis for the difference in nuclear location is uncertain, but
could reflect the presence of additional factors that can influence
maturation in vivo that are absent during maturation in vitro. The
difference may also reflect variability in the stage of differentiation/
maturation in SFDCs, which will not be synchronised to the extent
that occurs with in vitro systems, such as generation of MDDCs,
where the precursor monocytes will engage the stimuli for differ-
entiation contemporaneously.
The expression of PGDS in fresh SFDCs may be an important
observation. PGD2 has been shown to play an active role in the
resolution of experimentally induced inflammation in vivo.7
Furthermore, with DC isolated from other tissues, exogenous
PGD2 has been shown to retard DC migration and to induce
regulatory T cells through engagement of the prostanoid receptor
DP1.8 It is thus conceivable that endogenous PGD2 generated by
SFDCs may modulate immune responses within the synovium
through autocrine and paracrine effects. We have shown in a rat
model of polyarthritis that PGDS expression in DCs freshly
isolated from synovium-rich tissues of arthritic hind-feet
correlates inversely with clinical scores of disease severity.3 In
addition, we have previously observed that the expression of PGDS
by SFDCs and PGD2 levels in SF in patients with inflammatory
arthritis correlates inversely with the systemic disease activity
markers, C-reactive protein and erythrocyte sedimentation rate.1
Expression of PGDS by SFDCs was lost during 2 days of culture
in vitro and this was not affected by 1,25D or LPS alone or in
combination. By contrast, 1,25D upregulated PGDS in MDDCs,
although upregulation was largely abrogated by co-culture with LPS.
As the subjects under study were known either to have normal serum
vitamin D levels or to have been taking a regular vitamin D
supplement (data not shown), it can be inferred that in vivo
differentiation of SFDCs occurred in the setting of vitamin D
sufficiency. The extent to which 1,25D may influence PGDS
expression and other aspects of DC differentiation/maturation
in vivo is uncertain. However, the present findings suggest that
1,25D has different effects on the expression of a number of
inflammatory proteins, including PGDS, depending on the stage of
maturation of DCs and the co-stimuli present.
1,25D can modulate the immune response leading to immuno-
suppression.9,10 These immunomodulatory effects appeared most
pronounced when 1,25D is present during both differentiation and
maturation of DCs.11 However, such effects are not observed if the
TLR-4 and the vitamin D receptor are stimulated with their agonist
simultaneously.12,13 The immunomodulatory actions of 1,25D are
thus complex and appear to change in the presence of danger signals
such as TLR ligands.14 A protective effect of vitamin D has been
shown in relation to respiratory infections in children.15,16 At least
part of this effect may be attributed to effects of vitamin D on
expression of proteins, which mediate mucosal barrier defence.17 In
the present study, the cooperative interaction between 1,25D and the
bacterial pattern receptor stimulus LPS, with regard to expression of
IL6 and PGES by SFDCs and MDDCs, further supports the notion
that vitamin D status may favourably condition innate-immune
defence against pathogens.14 On the other hand, enhancement of
PGES expression by 1,25D during LPS activation of DCs may be
important in regulation of immune responses. For example, PGE2 has
been shown to redirect the differentiation of MDDCs towards
myeloid-derived suppressor cells.18 These MDDC suppressor cells
are involved in suppression of acute inflammatory mediators.19 IL6 is
considered to be an inflammatory cytokine and has been implicated
in autoimmune diseases and inflammation.20 However, IL6
suppresses DC activation/maturation and may in some settings act
as inflammation modulator.21 In the present study, due to limited
numbers of SFDCs, co-stimulatory molecules, inflammatory
cytokines and PGSs were studied at the mRNA level. It remains to











Figure 2 Comparison between morphology of SFDCs and MDDCs. Giemsa-stained cytospin preparations: (a) fresh SFDCs, (b) MDDCs from 7 days culture of
peripheral blood monocytes in granulocyte–macrophage colony-stimulating factor/IL-4, (c) SFDCs after 2 days culture with LPS, and (d) MDDCs after 2 days
culture with LPS. Because the density of cells would provide few examples at the magnification shown, the depicted fields have been supplemented by
examples (cells surrounded by inset borders) from other fields.
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release of inflammatory mediators in SFDCs and MDDCs as
measured at the protein level.
In a rat model of polyarthritis induced by intravenous injection of
arthritogenic T cells from syngeneic donor rats in the prodrome for
adjuvant-induced arthritis, we observed that vitamin D-replete
recipients developed less-severe arthritis than their vitamin
D-deficient counterparts. DC isolated from synovium-rich tissues
from the vitamin D-replete rats expressed substantially more PGDS
than DCs from synovium-rich tissues of vitamin D-deficient rats.3
While association does not establish causation, the known effects of
PGD2 in modulating DC and lymphocyte function and the
inflammation-resolving actions of PGD2 suggest a possible role for
PGD2 in disease control. In the above animal studies, the groups were
markedly different in vitamin D status (severe deficiency vs upper
normal range). By contrast, in human studies in rheumatoid arthritis
to date, where the effects of vitamin D have been less clear cut,
vitamin D deficiency has generally been less severe and serum
25 hydroxy-vitamin D levels in those regarded as replete, have often
been towards the low end of the normal reference range.22 Thus, the
comparisons have often been between moderate deficiency and
borderline sufficiency, with the latter possibly being suboptimal for
immunemodulatory and anti-inflammatory effects. In the present
study, the combinatory effects of 1,25D and LPS on the expression by
DCs of certain inflammatory proteins (IL6, PGES) suggest that
vitamin D could have proinflammatory effects through ampli-
fication of effector mechanisms in inflammatory diseases at least in
the presence of bacterial pattern receptor ligands. It is conceivable that
vitamin D may augment host defence through effects on pattern
receptor responses while modulating autoimmunity through other
mechanisms.5,6 Notwithstanding, the data are ambiguous with regard
to the benefit or otherwise of vitamin D supplements in rheumatoid
arthritis (and other autoimmune and inflammatory disease).
Appropriately designed clinical trials in rheumatoid arthritis and
other inflammatory diseases are therefore needed to determine the
place of vitamin D supplements and to define targets for vitamin D
status, as measured by serum assays of 25 hydroxy-vitamin D. Within
this small sample of patients with different arthropathies, the
responses seen by SFDCs were not obviously influenced by the type
of arthropathy or treatment.
In conclusion, SFDC and MDDC share many similarities with
regard to morphology, phenotype and basal expression of inflamma-
tory cytokines and PGSs. However, significant differences can occur in
expression of PGDS, the synthase for the inflammation-resolving
eicosanoid PGD2, which is expressed basally by SFDCs but not by
MDDCs. SFDCs and MDDCs also differ in responses to LPS. These
responses can be influenced by the biologically active form of vitamin
D, which can also induce PGDS in MDDCs. The findings highlight









































































Figure 3 Expression of co-stimulatory molecules by SFDCs and MDDCs. The effect of 1,25D and LPS on the expression of mRNA for co-stimulatory
molecules CD80 (a, b), CD83 (c, d) and CD86 (e, f) by SFDCs (a, c, e) and MDDCs (b, d, f). Meanþ s.e.m. *Po0.01, **Po0.001, ***Po0.0001, ns,
not significant.
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in order to complement studies of more conveniently obtained
MDDCs. The studies also draw attention to the potentially complex
effects of vitamin D on immune responses.
METHODS
Subjects
SF and paired PB samples were obtained from six patients with inflammatory
knee effusions. Demographic and clinical details are shown in Table 1. All
subjects gave informed consent, and the study protocol was approved by the
Human Research Ethics Committee, Royal Adelaide Hospital.
Isolation of SF myeloid DCs
Mononuclear cells were isolated from SF by density gradient centrifugation
over Lymphoprep, then incubated with a cocktail of (labelled) monoclonal
antibodies against CD11b (Alexa Fluor 488-lab), CD11c (phycoerythrin),
HLADR (PE-cy5) and CD14 (APC) for 45min at 4 1C, as described
previously.1 Cells were gated by size (Figure 1a) for sorting into CD11bþ
HLADRþ CD11cþ CD14 (DCs) and CD11bþ HLADRþ CD11cþ CD14þ
(monocytes) populations, using FACS Diva software (Becton Dickinson, San
Jose, CA, USA), as described previously (Figures 1b and c).1
Preparation of MDDCs
Lymphoprep was used to harvest PB mononuclear cells, from which, CD14þ
monocytes were isolated by positive magnetic selection using anti-CD14
microbeads, according to the supplier’s protocol (MiltenyiBiotec, Bergisch
Gladbach, Germany). The purity of the CD14þ cell fraction, as assessed by
flow cytometry using anti-CD14-FITC, was consistently more than 90%. To



















































































Figure 4 Expression of inflammatory cytokines by SFDCs and MDDCs. The effect of 1,25D and LPS on the expression of mRNA for the cytokines IL23
(a, b), IL1b (c, d), TNFa (e, f) and IL6 (g, h) by SFDCs (a, c, e, g) and MDDCs (b, d, f, h). Please note different scales have been used for SFDCs and
MDDCs (a–f) to show the pattern of expression of IL23, IL1b and TNFa. Meanþ s.e.m. *Po0.01, **Po0.001, ns, not significant.
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complete medium containing 10% fetal calf serum and 1mM sodium
pyruvate in the presence rhGM-CSF 100 ngml1 (kindly provided by
Dr T Hercus, Human Immunology, SA Pathology, Adelaide, Australia) and
rhIL-4 50ngml1 (PeproTech, Rocky Hill, NJ, USA) for 7 days. Medium
supplemented with cytokines was refreshed every 3rd day.
Culture of DCs
SFDCs and MDDCs, prepared as detailed above, were cultured for 48 h
in complete medium supplemented with 10% fetal calf serum alone or
with LPS (from Escherichia coli, Sigma, St Louis, MO, USA), at a final
concentration of 200 ngml1, in the presence or absence of 1,25D (Sigma)
10 nM l1, which is physiologically appropriate.23 Culture with medium
alone was used as a control.
Cytology
Cytospin smears prepared from fresh and cultured cells were fixed and stained
as described.24
RNA isolation and quantitative reverse transcription PCR analysis
of gene expression
Total RNA was extracted from fresh flow cytometrically sorted cell populations
or from cultured cells, using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA)
according to the manufacturer’s instructions. Total RNA was reverse tran-
scribed to cDNA and amplified using the two-step reverse transcription PCR
kit from Qiagen. RNA and cDNA quality was assessed using a NanoDrop 1000
spectrophotometer (ThermoFisher Scientific, Wilington, DE, USA) before
samples were frozen at 70 1C until further use. Gene expression levels were
investigated using commercially available specific primers for human genes
obtained from Qiagen, including PGDS (QT-00022043), PGES (QT00208607),
COX-2 (QT00040586), CD80 (QT00000497), CD83 (QT00069923), CD86
(QT00033915), IL1b (QT00021385), IL6 (QT00083720), IL12 (QT00000357),











































































Figure 5 Expression of prostaglandin synthases by SFDCs and MDDCs. The effect of 1,25D and LPS on the expression of mRNA for prostaglandin
synthases: cyclooxygenase (COX-2) (a, b), prostaglandin E-synthase (PGES) (c, d) and prostagandin D-synthase (PGDS) (e, f) by SFDC (a, c, e) and MDDCs
(b, d, f). Please note different scales have been used for SFDCs and MDDCs (a, b) to show the pattern of COX-2 expression. Meanþ s.e.m. *Po0.01,
**Po0.001, ***Po0.0001, NS, not significant.




Rheumatoid arthritis 22 DMARDþNSAIDþ fish oil
Rheumatoid arthritis 27 DMARDþ adalimumabþ fish oil
Psoriatic arthritis 6 DMARDþ vitamin Dþ fish oil
Psoriatic arthritis 12 Fish oil
B27þpauci-arthritis 18 DMARDþ vitamin Dþ fish oil
RNPþ polyarthritis 3 DMARDþNSAIDþ vitamin Dþ fish oil
Abbreviations: DMARD, disease-modifying anti-inflammatory drugs; NSAID, non-steroidal
anti-inflammatory drugs.
Adalimumab is a tumour necrosis factor inhibitor.
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(b-actin, QT01680476). Real-time PCR was performed using the QuantiFast
SYBR Green PCR kit (Qiagen) according to the supplier’s protocol, in a
Rottor-Gene 3000 real-time PCR machine (Corbett Research, New South
Wales, Australia). A minimum of three replicate samples were processed in
each experiment. Each PCR included a sample prepared without template and
a sample prepared without primers as negative controls. The thermal
conditions were 95 oC for 5min followed by 35 cycles of 95 1C for 10 s
and 60 1C for 30 s. PCR product quality was monitored using post-PCR melt
curve analysis. Fold changes were calculated using the formula 2(DCt), and
DCt¼Ct (target gene)Ct (b-actin). Ct is the cycle at which the threshold
line is crossed.25
Statistical analysis
All data were analysed using GraphPad Prism V5.0 (GraphPad Software Inc.,
San Diego, CA, USA). Quantitative real-time reverse transcription PCR signals
were normalised to b-actin. One-way analysis of variance with Neuman–Keuls
test was used to determine significant differences between the groups. Po0.05
was considered significant.
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